

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES  
AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

**INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED  
30 JUNE 2023  
TOGETHER WITH REVIEW REPORT**

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC  
REAGENTS (RAMEDA) (S.A.E)**

---

**Interim condensed separate financial statements**

**For the three-month and six-month periods ended 30 June 2023**

<b>Table of Contents</b>	<b>Page</b>
Review Report	3
Interim Condensed Separate Statement of Financial Position	4
Interim Condensed Separate Statement of Profit or Loss	5
Interim Condensed Separate Statement of Comprehensive Income	6
Interim Condensed Separate Statement of Changes in Equity	7
Interim Condensed Separate Statement of Cash Flows	8
Notes to the Interim Condensed Separate Financial Statements	9 -25

**INDEPENDENT AUDITOR'S REVIEW REPORT  
TO THE MEMBERS OF THE BOARD OF DIRECTORS OF TENTH OF RAMADAN FOR  
PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)  
ON THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS**

**Introduction**

We have reviewed the accompanying interim condensed separate financial position of **TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)** as at 30 June 2023 and the related interim condensed separate statements of profit or loss, comprehensive income, changes in equity and cash flows for the three-month and six month periods then ended, and a summary of significant accounting policies and other explanatory notes. Management is responsible for the preparation and fair presentation of these interim condensed separate financial statements in accordance with Egyptian Accounting Standards. Our responsibility is to express a conclusion on these interim condensed separate financial statements based on our review.

**Scope of Review**

We conducted our review in accordance with Egyptian Standard on Review Engagements No. 2410, "Review of Interim financial statements performed by the independent auditor of the entity." A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Egyptian Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on these interim financial statements.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed separate financial statements does not give a true and fair view, in all material respects, of the financial position of the entity as at 30 June 2023, and of its financial performance and its cash flows for the six month period ended 30 June 2023 in accordance with Egyptian Accounting Standard No. (30) "Interim Financial Statements".



Cairo: 15 August 2023


**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

**INTERIM CONDENSED SEPARATE STATEMENT OF FINANCIAL POSITION**  
As at 30 June 2023

	Notes	30 June 2023 EGP	31 December 2022 EGP
<b>ASSETS</b>			
<b>Non-current assets</b>			
Fixed assets & Assets under construction	(5)	563,703,754	540,765,324
Right of use assets	(6-A)	14,408,219	16,215,560
Intangible assets	(7)	575,923,662	438,483,986
Investment in subsidiaries		1,461,800	1,461,800
<b>Total non-current assets</b>		<b>1,155,497,435</b>	<b>996,926,670</b>
<b>Current assets</b>			
Inventories	(8)	383,414,359	335,894,054
Trade and notes receivable	(9)	1,074,445,828	893,048,470
Treasury Bills	(10)	295,291,923	361,862,202
Due from related parties	(28)	25,046,446	24,422,539
Prepayments and other receivables		101,999,106	75,873,064
Cash on hand and at banks	(11)	105,067,425	65,599,444
<b>Total current assets</b>		<b>1,985,265,087</b>	<b>1,756,699,773</b>
<b>TOTAL ASSETS</b>		<b>3,140,762,522</b>	<b>2,753,626,443</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Capital	(14)	252,112,680	250,000,000
Paid under capital increase	(14)	-	160,606
Legal reserve		125,000,000	125,000,000
General reserve	(15)	412,394,657	397,521,390
Treasury Shares	(16)	(65,926,198)	(65,926,198)
Share based payments reserve	(17)	5,108,906	14,873,267
Other reserves		278,952	278,952
Profit for the period and retained earnings		885,379,478	788,698,090
<b>Total equity</b>		<b>1,614,348,475</b>	<b>1,510,606,107</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
Lease liabilities	(6-B)	14,291,101	16,343,678
Deferred tax liabilities	(25)	54,219,731	51,555,823
<b>Total non-current liabilities</b>		<b>68,510,832</b>	<b>67,899,501</b>
<b>Current liabilities</b>			
Provisions	(12)	14,158,105	14,158,105
Credit facilities	(18)	1,063,815,632	904,752,873
Current lease liabilities	(6-B)	4,219,014	3,663,480
Trade, notes & other payables	(13)	340,687,241	204,600,751
Due to related parties	(28)	6,763,515	-
Income taxes payable		28,259,708	47,945,626
<b>Total current liabilities</b>		<b>1,457,903,215</b>	<b>1,175,120,835</b>
<b>TOTAL LIABILITIES</b>		<b>1,526,414,047</b>	<b>1,243,020,336</b>
<b>TOTAL LIABILITIES AND EQUITY</b>		<b>3,140,762,522</b>	<b>2,753,626,443</b>

Finance Director

Mohamed Abo Amira



Board Member

Amr Abdallah Morsy



The accompanying notes from (1) to (29) are an integral part of these interim condensed separate financial statements.  
Review Report attached.

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

**INTERIM CONDENSED SEPARATE STATEMENT OF PROFIT OR LOSS**  
For the three-month and six-month periods ended 30 June 2023

	Notes	Six Months Ended		Three Months Ended	
		30 June 2023 EGP	30 June 2022 EGP	30 June 2023 EGP	30 June 2022 EGP
Revenues	(19)	838,996,954	708,115,660	449,318,991	365,616,427
Cost of revenues	(20)	(459,786,994)	(365,944,477)	(244,510,433)	(194,939,317)
<b>GROSS PROFIT</b>		<b>379,209,960</b>	<b>342,171,183</b>	<b>204,808,558</b>	<b>170,677,110</b>
Selling and marketing expenses	(21)	(154,802,138)	(135,577,407)	(86,769,580)	(72,437,811)
General and administrative expenses	(22)	(40,998,988)	(30,679,099)	(22,142,740)	(16,208,729)
Other income		1,083,351	5,032,981	542,952	4,756,341
<b>Operating profit</b>		<b>184,492,185</b>	<b>180,947,658</b>	<b>96,439,190</b>	<b>86,786,911</b>
Finance income	(23)	30,771,182	27,666,965	15,060,356	13,706,278
Finance expenses	(24)	(76,134,103)	(43,671,024)	(45,015,977)	(21,483,721)
Net foreign exchange gain (losses)		18,934,545	7,325,339	(333,550)	(29,608)
<b>Net Finance expense</b>		<b>(26,428,376)</b>	<b>(8,678,720)</b>	<b>(30,289,171)</b>	<b>(7,807,051)</b>
Impairment of trade and notes receivable	(9)	(1,744,133)	(1,000,000)	(355,723)	-
Share Based payment expenses	(17)	(6,536,280)	(6,536,280)	(2,074,300)	(6,536,280)
Contribution for health insurance		(2,213,275)	(1,848,702)	(1,148,186)	(956,223)
<b>PROFITS FOR THE PERIOD BEFORE INCOME TAXES</b>		<b>147,570,121</b>	<b>162,883,956</b>	<b>62,571,810</b>	<b>71,487,357</b>
Income taxes	(25)	(34,126,233)	(37,644,633)	(14,523,635)	(16,664,396)
<b>PROFITS FOR THE PEIROD</b>		<b>113,443,888</b>	<b>125,239,323</b>	<b>48,048,175</b>	<b>54,822,961</b>
Basic Earnings Per Share	(26)	0.1159	0.1265	0.0491	0.0554
Diluted Earnings Per Share	(26)	0.1151	0.1256	0.0487	0.0550

Finance Director

Mohamed Abo Amira



Board Member

Amr Abdallah Morsy



The accompanying notes from (1) to (29) are an integral part of these interim condensed separate financial statements.

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

**INTERIM CONDENSED SEPARATE STATEMENT OF COMPREHENSIVE INCOME**

For the three-month and six-month periods ended 30 June 2023

	<b>Six Months Ended</b>		<b>Three Months Ended</b>	
	<b>30 June 2023</b>	30 June 2022	<b>30 June 2023</b>	30 June 2022
	<b>EGP</b>	EGP	<b>EGP</b>	EGP
<b>PROFITS FOR THE PERIOD</b>	<b>113,443,888</b>	125,239,323	<b>48,048,175</b>	54,822,961
OTHER COMPREHENSIVE INCOME	-	-	-	-
<b>TOTAL COMPREHENSIVE INCOME</b>	<b>113,443,888</b>	125,239,323	<b>48,048,175</b>	54,822,961

The accompanying notes from (1) to (29) are an integral part of these interim condensed separate financial statements.

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)****INTERIM CONDENSED SEPARATE STATEMENT OF CHANGES IN EQUITY**

For the three-month and six-month periods ended 30 June 2023

	<b>Paid up Capital</b>	<b>Paid under capital increase</b>	<b>Legal reserve</b>	<b>General reserve</b>	<b>Treasury Shares</b>	<b>Share Based Payment</b>	<b>Other Reserves</b>	<b>Retained earnings</b>	<b>Total</b>
	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>
Balance as at 1 January 2022	250,000,000	-	26,446,118	486,965,000	-	-	278,952	587,471,195	1,351,161,265
Transferred to legal reserve	-	-	9,110,272	-	-	-	-	(9,110,272)	-
Acquisition of treasury shares	-	-	-	-	(39,695,319)	-	-	-	(39,695,319)
Share based Payment reserve	-	-	-	-	-	6,536,280	-	-	6,536,280
Dividend distributions	-	-	-	-	-	-	-	(24,307,500)	(24,307,500)
Total comprehensive income for the period	-	-	-	-	-	-	-	125,239,323	125,239,323
<b>Balance as at 30 June 2022</b>	<b>250,000,000</b>	<b>-</b>	<b>35,556,390</b>	<b>486,965,000</b>	<b>(39,695,319)</b>	<b>6,536,280</b>	<b>278,952</b>	<b>679,292,746</b>	<b>1,418,934,049</b>
Balance as at 1 January 2023	<b>250,000,000</b>	<b>160,606</b>	<b>125,000,000</b>	<b>397,521,390</b>	<b>(65,926,198)</b>	<b>14,873,267</b>	<b>278,952</b>	<b>788,698,090</b>	<b>1,510,606,107</b>
Paid under capital increase (Note 14)	-	<b>1,952,074</b>	-	-	-	-	-	-	<b>1,952,074</b>
Transferred from paid under increase to capital increase (Note 14)	<b>2,112,680</b>	<b>(2,112,680)</b>	-	-	-	-	-	-	-
Share based Payment reserve	-	-	-	-	-	<b>5,108,906</b>	-	-	<b>5,108,906</b>
Transferred from Share based payment reserve to General reserve	-	-	-	<b>14,873,267</b>	-	<b>(14,873,267)</b>	-	-	-
Dividend distributions	-	-	-	-	-	-	-	<b>(16,762,500)</b>	<b>(16,762,500)</b>
Total comprehensive income for the period	-	-	-	-	-	-	-	<b>113,443,888</b>	<b>113,443,888</b>
<b>Balance as at 30 June 2023</b>	<b>252,112,680</b>	<b>-</b>	<b>125,000,000</b>	<b>412,394,657</b>	<b>(65,926,198)</b>	<b>5,108,906</b>	<b>278,952</b>	<b>885,379,478</b>	<b>1,614,348,475</b>

The accompanying notes from (1) to (29) are an integral part of these interim condensed separate financial statements.

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### INTERIM CONDENSED SEPARATE STATEMENT OF CASH FLOWS

For the three-month and six-month periods ended 30 June 2023

	Notes	30 June 2023 EGP	30 June 2022 EGP
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profits for the period before income taxes		147,570,121	162,883,956
<b>Adjustments to reconcile profit before tax to net cash flow:</b>			
Net foreign exchange differences		(6,685,761)	(4,485,533)
Depreciation and amortization	(5,6,7)	33,023,533	30,621,446
Share based payment expense		6,536,280	6,536,280
Provision charged	(12)	-	(327,577)
Impairment of trade and notes receivable	(9)	1,744,133	1,000,000
Impairment of inventory	(8)	17,112,711	9,881,874
Finance income		(30,440,081)	(27,665,331)
Finance expenses	(24)	75,066,883	42,629,390
Unwinding interests of lease liabilities	(24)	1,067,220	1,041,634
Loss / (Gain) from sale of fixed assets		(108,473)	109,781
		<b>244,886,566</b>	<b>222,225,920</b>
Change in inventories		(56,037,412)	(36,246,673)
Used from inventory provision		(8,595,604)	(10,279,028)
Change in trade and notes receivable		(183,141,491)	(53,548,544)
Used from trade and notes receivable		-	(1,179,727)
Change in prepayments and other receivables		(13,807,393)	5,455,676
Change in trade, notes and other payable		123,111,018	71,882,031
Change in due to related parties		6,763,515	(290,361)
<b>Cash flows provided from operating activities</b>		<b>113,179,199</b>	<b>198,019,294</b>
Debit interests paid		(63,518,786)	(39,254,674)
Income taxes paid		(51,148,243)	(37,585,082)
<b>NET CASH FLOWS (USED IN) RESULTED FROM OPERATING ACTIVITIES</b>		<b>(1,487,830)</b>	<b>121,179,538</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Payments to acquire fixed assets	(5)	(8,930,795)	(9,430,530)
Payments to acquire assets under construction	(5)	(32,463,892)	(3,720,576)
Payments to acquire intangible assets	(7)	(150,000,000)	(89,937,692)
Payment to acquire treasury bills	(10)	(328,783,359)	(437,040,964)
Matured treasury bills collection	(10)	366,800,000	496,100,000
Sale of treasury bills		46,675,071	-
Proceeds from sale of fixed assets	(5)	117,576	21,851
Investment in term deposit	(11)	642,072	(290)
<b>NET CASH FLOWS (USED IN) INVESTING ACTIVITIES</b>		<b>(105,943,327)</b>	<b>(44,008,201)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Payments to capital increase	(14)	2,112,680	-
Credit facilities used	(18)	692,541,134	619,587,472
Payment of credit facilities	(18)	(533,478,375)	(611,168,930)
Payment of long-term loans		-	(21,949,676)
Acquisition of Treasury shares		-	(39,695,319)
Change in due from related parties	(28)	(623,907)	3,824,879
Dividends paid during the period		(16,762,500)	(24,307,500)
Lease payments paid during the period	(6)	(2,772,977)	(2,541,143)
<b>NET CASH FLOWS RESULTED FROM (USED IN) FINANCING ACTIVITIES</b>		<b>141,016,055</b>	<b>(76,250,217)</b>
<b>Net change in cash and cash equivalent during the period</b>		<b>33,584,898</b>	<b>921,120</b>
Net foreign exchange difference		6,685,761	4,485,533
Cash and cash equivalent - beginning of the period		18,062,727	13,106,409
<b>CASH AND CASH EQUIVALENT - END OF THE PERIOD</b>	(11)	<b>58,333,386</b>	<b>18,513,062</b>

The accompanying notes from (1) to (29) are an integral part of these interim condensed separate financial statements.



## **TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

---

### **NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS**

For the three-month and six-month periods ended 30 June 2023

#### **1- BACKGROUND**

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) was established under the provisions of Law No. 43 of 1974.

The Company was registered in the commercial registry under No.84008 on 15 January 1986.

The listing of Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) on the Egyptian stock exchange was approved in 26 November 2019 according to resolution of listing committee of Egyptian stock exchange.

The registered office is located at plot No. 5 Second Industrial Zone, 6th of October City – Giza– Egypt.

The Company is principally engaged in:

1. Producing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use.
2. Producing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals.
3. Importing pharmaceutical reagents and raw materials necessary for serving the Company's purposes without trading.
4. Producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others.
5. Producing food supplements for human use for others and by others.

The financial statements for the period ended 30 June 2023 were authorized for issuance in accordance with a resolution of the Board of Directors' dated 14 August 2023.

#### **2- SIGNIFICANT ACCOUNTING POLICIES**

##### **2-1 BASIS OF PREPARATION**

The separate financial statements are prepared under the going concern assumption on a historical cost basis and The Company is not subject to any significant seasonal or cyclical effects.

The separate financial statements are prepared and presented in Egyptian pounds, which is the Company's functional currency.

The separate financial statements of the Company have been prepared in accordance with the Egyptian accounting standards Num (30) and the applicable laws and regulations, The condensed financial statements do not include all the financial statements and disclosures required in the annual financial statements and should be read in conjunction with the financial statements for the year ending December 31, 2022. In addition, the results of the interim period ending March 31, 2023, may not be considered an accurate indication of the expected results for the financial year. On December 31, 2023.

##### **2-2 SIGNIFICANT ACCOUNTING POLICIES**

The accounting policies used in the preparation of the condensed Separate interim financial statements are consistent with those used in the preparation of the separate financial statements for the year ending on December 31, 2023.

There is no change in the accounting policies used as the company did not apply the new changes in the accounting standards.

##### **2-3 CHANGES IN ACCOUNTING POLICIES**

The Prime Minister's Decision No. 883 of 2023 was issued on March 6, 2023, to amend the Egyptian Accounting Standards, and accordingly, the Introductory Appendix in the Egyptian Accounting Standards issued by the Minister of Investment's Decision No. 110 of 2015 is replaced by a Introductory Appendix to the Egyptian Accounting Standards Amendments and the Introductory Appendix 2023 Amendments.

It replaces the following standards: (10) fixed assets, (23) intangible assets, (34) Investment properties, (35) agriculture, and (36) Exploration for and evaluation of mineral resources, from the aforementioned Egyptian accounting standards, with standards Attached to the Prime Minister's decision and the Introductory appendix Amendments 2023.

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)****NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS**

For the three-month and six-month periods ended 30 June 2023

**2-3 CHANGES IN ACCOUNTING POLICIES (CONT)**

Set out below are the amended standards and interpretations issued,

**Amended Egyptian accounting standard 10: Fixed assets**

Egyptian accounting standard 10 has been amended and reissued in 2023 and is effective for the financial periods beginning on or after 1 January 2023. Retrospective application is required with restating the comparative information.

The amendments allow using the revaluation model for the subsequent measurement of fixed assets. The gains and losses resulting from the revaluation of fixed assets are recognized within other comprehensive income and accumulated as equity in the "revaluation surplus" account.

There is no impact on the company's separate financial statements, as the company chose not to change the current accounting policy and did not apply the alternative accounting treatment.

**Amended Egyptian accounting standard 23: Intangible assets**

Egyptian accounting standard 23 has been amended and reissued in 2023 and is effective for the financial periods beginning on or after 1 January 2023. Retrospective application is required with restating the comparative information.

The amendments allow using the revaluation model for the subsequent measurement of intangible assets. The gains and losses resulting from the revaluation of intangible assets are recognized within other comprehensive income and accumulated as equity in the "revaluation surplus" account.

There is no impact on the company's separate financial statements, as the company chose not to change the current accounting policy and did not apply the alternative accounting treatment.

**Amended Egyptian accounting standard 34: Investment properties**

Egyptian accounting standard 34 has been amended and reissued in 2023 and is effective for the financial periods beginning on or after 1 January 2023. Retrospective application is required with restating the comparative information.

The amendments allow entities to using the fair value model option for subsequent measurement of their real estate investments, with REITs required only to use the fair value model for subsequent measurement of all their real estate assets .

The increase in fair value is recognized for the subsequent measurement of real estate investment within items within other comprehensive income, rather than profits or losses, and accumulated within equity in the account of "surplus valuation of real estate investment at fair value".

There is no impact on the company's separate financial statements

**Amended Egyptian accounting standard 35: Agriculture**

Egyptian accounting standard 35 has been amended and reissued in 2023 and is effective for the financial periods beginning on or after 1 January 2023. Retrospective application is required with restating comparative figures.

Fruit plants were excluded from EAS 35: Agriculture to be under the scope of EAS 10: Fixed Assets. There is no impact on the company's separate financial statements.

**Amended Egyptian accounting standard 36: Exploration for and evaluation of mineral resources**

Egyptian accounting standard 36 has been amended and reissued in 2023, is effective for the financial periods beginning on or after 1 January 2023. Retrospective application is required with restating the comparative information.

The amendments allow using the revaluation model for the subsequent measurement of its mineral resources. The gains and losses resulting from the revaluation of mineral resources are recognized within other comprehensive income and accumulated as equity in the "revaluation surplus" account. There is no impact on the company's separate financial statements.

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)****NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS**

For the three-month and six-month periods ended 30 June 2023

**2-3 CHANGES IN ACCOUNTING POLICIES (CONT)**

Set out below are standards and interpretations that have been issued, but remain not effective, as at the date of issuance of these financial statements.

**Egyptian accounting standard 50: Insurance contracts**

Egyptian accounting standard 50 "Insurance Contracts" which replaced the Egyptian Accounting Standard 37 "Insurance Contracts". EAS 50 was issued in 2023, and effective beginning on or after July 1, 2024 in Egypt. Early application of the standard is allowed

This standard defines the proof principles of insurance contracts falling within the scope of this standard, and determines their measurement, presentation and disclosure. The objective of the standard is to ensure that the entity provides appropriate information that truthfully reflects those contracts. This information provides the users of the financial statements with basis for assessing the impact of such insurance contracts on the entity's financial position, financial performance and cash flows.

There is no impact on the company's separate financial statements.

**3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES**

The preparation of these separate financial statements requires management to make judgments and estimates that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures and the disclosure of contingent liabilities at the reporting date. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the assets or liabilities affected in future periods.

Estimates and their underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised.

The key judgments and estimates that have a significant impact on the separate financial statements of the Company are discussed below:

**3-1 Judgments****Revenue Recognition for sale of goods**

In making their judgment, the management considered the detailed criteria for the recognition of revenue from the sale of goods as set out in "EAS 48 Revenue from contracts with customers" including the judgement about whether significant risks and rewards have been transferred.

**3-2- Estimates****Impairment of trade and other receivables**

An estimate of the collectible amount of trade and other receivables is made when collection of the full amount is no longer probable. For individually significant amounts, this estimate is performed on an individual basis. Amounts which are not individually significant, but are past due, are assessed collectively and a provision is applied according to the length of time past due, based on historical recovery rates.

**Provision for sales returns**

The Company's management determines the estimates provision for the expected sales returns. This estimate is determined after considering the past experience of sales returns and sales volume and expiry dates of the products sold. The management periodically reviews the estimated provision amount to ensure that provision is adequate to cover the sales return.

**Useful lives of fixed assets**

The Company's management determines the estimated useful lives of its fixed assets for calculating depreciation. This estimate is determined after considering the expected usage of the asset or physical wear and tear. The management periodically reviews the estimated useful lives and the depreciation method to ensure that the method and the period of depreciation are consistent with the expected pattern of economic benefits from these assets.

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### 3- SIGNIFICANT ACCOUNTING JUDGMENTS AND ESTIMATES (CONT)

##### Useful lives of intangible assets

The useful lives of intangible assets are assessed as either finite or indefinite.

The assessment of indefinite life is reviewed annually to determine whether indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis.

The management periodically reviews the estimated useful lives and the amortization method to ensure that the method and the period of amortization are consistent with the expected pattern of economic benefits from these assets.

##### Taxes

The Company is subject to income taxes in Egypt. A significant judgment is required to determine the total provision for current and deferred taxes. The Company establishes provision, based on reasonable estimates, for possible consequences of audits by the tax authorities in Egypt. The amount of such a provision is based on various factors, such as experience of previous tax audits and different interpretations of tax regulations by the Company and the responsible tax authority. Such differences of interpretations may be on a wide variety of issues depending on the conditions prevailing in Egypt.

Deferred tax assets are recognized for unused accumulated tax losses to the extent that it is probable that taxable profits will be available against which the losses can be utilized. A significant management judgment is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

##### Impairment of non-financial assets

The Company assesses whether there are any indicators of impairment for all non-financial assets at each reporting date. The non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. When value in use calculations is undertaken, management estimates the expected future cash flows from the asset or cash-generating unit and chooses a suitable discount rate in order to calculate the present value of those cash flows

#### 4- SEGMENT INFORMATION

Currently the Company's primary business segment is the production and selling of pharmaceutical products which contributes to 91% of total revenue and balance 9% is contributed by toll manufacturing services (30 June 2022: 93% and 7% respectively). The Company's management monitors the business under two segments, "production and selling of pharmaceutical products" and "manufacturing for others" (Toll manufacturing) for the purpose of making business decisions. Accordingly, the Company's revenues during the period ended 30 June 2023 were reported under two segments in the separate financial statements.

The Company produces and sells several products and renders services as follows:

Period	Services		Sales of pharmaceutical products			Total EGP
	Toll Manufacturing "Domestic" EGP	Export EGP	Domestic			
			Private sales EGP	Tenders EGP		
30 June 2023	<u>73,272,538</u>	<u>79,209,215</u>	<u>591,347,400</u>	<u>95,167,801</u>	<u>838,996,954</u>	
30 June 2022	<u>51,933,190</u>	<u>55,762,075</u>	<u>494,741,331</u>	<u>105,679,064</u>	<u>708,115,660</u>	

Revenue from the top five customers represented 79% of total pharmaceutical products revenues (31 March 2022: 78%).

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)****NOTES TO THE INTERIM CONDENSED INTERIM SEPARATE FINANCIAL STATEMENTS**

For the three-month and six-month periods ended 30 June 2023

**5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION**

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
As of 1 January 2023	18,637,425	279,172,534	444,859,590	16,305,904	31,982,677	7,345,392	33,111,400	12,858,215	844,273,137
Additions	-	2,992,934	2,414,929	-	823,924	1,671,810	1,027,198	32,463,892	41,394,687
Transferred from assets under construction	-	699,242	88,436	-	-	-	1,414,922	(2,202,600)	-
Disposals	-	-	(4,361,961)	(245,740)	-	-	(21,966)	-	(4,629,667)
<b>As of 30 June 2023</b>	<b>18,637,425</b>	<b>282,864,710</b>	<b>443,000,994</b>	<b>16,060,164</b>	<b>32,806,601</b>	<b>9,017,202</b>	<b>35,531,554</b>	<b>43,119,507</b>	<b>881,038,157</b>
Accumulated depreciation									
As of 1 January 2023	-	(74,889,887)	(182,460,484)	(11,707,422)	(11,027,525)	(2,818,251)	(20,604,244)	-	(303,507,813)
Depreciation for the period	-	(4,474,716)	(10,076,261)	(431,647)	(1,513,347)	(366,661)	(1,584,522)	-	(18,447,154)
Disposals	-	-	4,361,384	245,740	-	-	13,440	-	4,620,564
<b>As of 30 June 2023</b>	<b>-</b>	<b>(79,364,603)</b>	<b>(188,175,361)</b>	<b>(11,893,329)</b>	<b>(12,540,872)</b>	<b>(3,184,912)</b>	<b>(22,175,326)</b>	<b>-</b>	<b>(317,334,403)</b>
<b>Net book value as of 30 June 2023</b>	<b>18,637,425</b>	<b>203,500,107</b>	<b>254,825,633</b>	<b>4,166,835</b>	<b>20,265,729</b>	<b>5,832,290</b>	<b>13,356,228</b>	<b>43,119,507</b>	<b>563,703,754</b>

- The cost of fixed assets as of 30 June 2023 includes EGP 107,458,576 which represents fully depreciated assets that are still in use.
- The cost of asset under construction as of 30 June 2023 includes impairment by EGP 686,437, (EGP 686,437 as at 31 December 2022).

Depreciation for the period was allocated to the statement of profit or loss as follows:

Gain from sale of fixed assets was calculated as follows:

	30 June 2023	30 June 2023	
	EGP	EGP	
Cost of revenue	16,967,460	Cost of disposed assets	4,629,667
Selling and marketing expenses	487,126	Accumulated depreciation of disposed assets	(4,620,564)
General and administrative expenses	992,568	Net book value of disposed assets	9,103
	<b>18,447,154</b>	Proceeds from sale of fixed assets	<b>117,576</b>
		Gain from sale of fixed assets	<b>108,473</b>

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)****NOTES TO THE INTERIM CONDENSED INTERIM SEPARATE FINANCIAL STATEMENTS**

For the three-month and six-month periods ended 30 June 2023

**5- FIXED ASSETS AND ASSETS UNDER CONSTRUCTION (CONTINUED)**

	Freehold Land	Buildings	Machinery and equipment	Transportation and dragging equipment	Laboratory equipment	Tools	Office furniture and fixtures	Assets under construction	Total
	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP	EGP
Cost									
As of 1 January 2022,	18,637,425	273,341,106	414,773,502	13,369,898	28,261,762	6,022,977	29,123,411	27,041,385	810,571,466
Additions	-	5,274,519	9,935,733	1,898,136	2,181,576	1,333,683	4,145,679	9,606,254	34,375,580
Transferred from assets under construction	-	556,909	20,329,505	1,037,870	1,811,035	-	54,105	(23,789,424)	-
Disposals	-	-	(179,150)	-	(271,696)	(11,268)	(211,795)	-	(673,909)
As of 31 December 2022,	<u>18,637,425</u>	<u>279,172,534</u>	<u>444,859,590</u>	<u>16,305,904</u>	<u>31,982,677</u>	<u>7,345,392</u>	<u>33,111,400</u>	<u>12,858,215</u>	<u>844,273,137</u>
Accumulated depreciation									
As of 1 January 2022,	-	(66,075,076)	(163,135,409)	(10,890,741)	(8,406,398)	(2,234,098)	(17,874,916)	-	(268,616,638)
Depreciation for the year	-	(8,814,811)	(19,475,517)	(816,681)	(2,800,934)	(588,204)	(2,917,802)	-	(35,413,949)
Disposals	-	-	150,442	-	179,807	4,051	188,474	-	522,774
As of 31 December 2022,	<u>-</u>	<u>(74,889,887)</u>	<u>(182,460,484)</u>	<u>(11,707,422)</u>	<u>(11,027,525)</u>	<u>(2,818,251)</u>	<u>(20,604,244)</u>	<u>-</u>	<u>(303,507,813)</u>
Net book value as of 31 December 2022	<u>18,637,425</u>	<u>204,282,647</u>	<u>262,399,106</u>	<u>4,598,482</u>	<u>20,955,152</u>	<u>4,527,141</u>	<u>12,507,156</u>	<u>12,858,215</u>	<u>540,765,324</u>

- The cost of fixed assets as of 31 December 2022 includes EGP 110,490,122 which represents fully depreciated assets that are still in use.

Depreciation for the year was allocated to the statement of profit or loss as follows:

	31 December 2022 EGP
Cost of revenue	32,581,460
Selling and marketing expenses	825,673
General and administrative expenses	2,006,816
	<u>35,413,949</u>

Loss from sale of fixed assets was calculated as follows:

	31 December 2022 EGP
Cost of disposed assets	673,909
Accumulated depreciation of disposed assets	(522,774)
Net book value of disposed assets	151,135
Proceeds from sale of fixed assets	22,850
Loss from sale of fixed assets	<u>(128,285)</u>

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### 6- LEASES

Right of use assets are scientific rental offices, operating leases, and warehouses

##### A) Right of use assets

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Cost at 1 January 2023	27,817,376	20,558,589
Additions	208,714	7,258,787
<b>Total Cost as of 30 June 2023</b>	<b>28,026,090</b>	<b>27,817,376</b>
Accumulated amortization at 1 January 2023	(11,601,816)	(7,526,230)
Amortization for period/year	(2,016,055)	(4,075,586)
<b>Accumulated amortization as of 30 June 2023</b>	<b>(13,617,871)</b>	<b>(11,601,816)</b>
<b>Net book value as of 30 June 2023</b>	<b>14,408,219</b>	<b>16,215,560</b>

##### B) Lease liability

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
<b>Opening balance as of 1 January 2023</b>	<b>20,007,158</b>	<b>15,386,755</b>
Additions	208,714	7,258,787
Unwinding interests recognized during the period	1,067,220	2,551,333
Lease payments paid during the period	(2,772,977)	(5,189,717)
<b>As at 30 June 2023</b>	<b>18,510,115</b>	<b>20,007,158</b>
<b>Deduct: Current balance</b>	<b>4,219,014</b>	<b>3,663,480</b>
<b>Non-current balance</b>	<b>14,291,101</b>	<b>16,343,678</b>

#### 7- INTANGIBLE ASSETS

	<i>Registration Rights</i>	
	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Cost as at 1 January 2023	494,151,784	400,271,629
Additions	150,000,000	93,880,155
<b>Total cost as at 30 June 2023</b>	<b>644,151,784</b>	<b>494,151,784</b>
Accumulated amortization as at 1 January 2023	(55,667,798)	(30,830,773)
Amortization for the period/year	(12,560,324)	(24,837,025)
<b>Accumulated amortization as at 30 June 2023</b>	<b>(68,228,122)</b>	<b>(55,667,798)</b>
<b>Net book value as at 30 June 2023</b>	<b>575,923,662</b>	<b>438,483,986</b>

- The balance of the intangible assets represents the cost of acquiring the registration rights of certain pharmaceutical products and is amortized using the straight-line method over their useful life (20 years).
- Management estimate the expected future benefit of the registration rights to be utilize over 20 years, and assessed for impaired whenever there is an indication that the economic benefit of the product is impaired.
- Intangible asset balance includes registration right assets under approval amounted to EGP 34,917,222 (31 December 2022: EGP 34,917,222).

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

**NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS**

For the three-month and six-month periods ended 30 June 2023

**8- INVENTORIES**

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Raw materials	130,352,277	127,123,447
Packing and packaging materials	77,734,840	66,850,553
Spare parts	19,477,737	19,009,433
Finished goods	115,648,905	77,537,207
Work in progress	46,455,330	51,192,105
Goods in transit	12,738,367	4,657,299
Inventory with others	180,370	180,370
	<u>402,587,826</u>	<u>346,550,414</u>
Write down in inventories	<u>(19,173,467)</u>	<u>(10,656,360)</u>
	<u><b>383,414,359</b></u>	<u><b>335,894,054</b></u>

The movement in the write down in value of inventories is as follows:

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Beginning balance	(10,656,360)	(11,073,894)
Charge during the period/year	(17,112,711)	(19,808,279)
Used of inventory provision	8,595,604	20,225,813
Ending balance	<u>(19,173,467)</u>	<u>(10,656,360)</u>

The write down in inventories during the period/year, if any, is included in the cost of sales.

**9- TRADE AND NOTES RECEIVABLE**

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Trade receivable	336,630,733	254,831,970
Trade receivable – toll manufacturing	32,437,285	31,131,130
Notes receivable	717,953,656	617,917,083
	<u>1,087,021,674</u>	<u>903,880,183</u>
Impairment of trade and notes receivable	<u>(12,575,846)</u>	<u>(10,831,713)</u>
	<u><b>1,074,445,828</b></u>	<u><b>893,048,470</b></u>

Notes receivable amounting to 492.5 MEGP are mortgage as a guarantee for the credit facilities (Note 18).

The movement of the impairment in value of trade receivable is as follows:

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Balance as at 1 January 2023	(10,831,713)	(8,434,594)
Charged during the period	(1,744,133)	(3,576,846)
Used provision	-	1,179,727
Ending balance	<u>(12,575,846)</u>	<u>(10,831,713)</u>



## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### 10- TREASURY BILLS

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Treasury bills	<b>326,400,000</b>	378,900,000
Unearned interest	<b>(31,108,077)</b>	(17,037,798)
	<b>295,291,923</b>	361,862,202

#### 11- CASH ON HAND AND AT BANKS

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
<b>a) Egyptian Pounds</b>		
Cash on hand	<b>81,514</b>	2,020,529
Current accounts	<b>16,120,975</b>	4,011,357
Checks under collection	<b>26,397,390</b>	7,179,075
Term deposits (Maturing within 3 months)	<b>399,039</b>	394,811
	<b>42,998,918</b>	13,605,772
<b>b) Foreign currencies</b>		
Cash on hand	<b>309,330</b>	12,815
Current accounts	<b>15,424,177</b>	4,999,557
Term deposits (Maturing within 3 months)	<b>46,335,000</b>	46,981,300
	<b>62,068,507</b>	51,993,672
	<b>105,067,425</b>	65,599,444

Cash balances are denominated in the following currencies:

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Egyptian pound (EGP)	<b>42,998,918</b>	13,605,772
US dollar (USD)	<b>61,453,722</b>	51,964,068
Euro (EUR)	<b>614,785</b>	29,604
	<b>105,067,425</b>	65,599,444

For the purpose of cash flow statements, cash and cash equivalents consist of following.

	<i>30 June 2023</i>	<i>30 June 2022</i>
	<i>EGP</i>	<i>EGP</i>
Cash in hand	<b>390,844</b>	2,883,057
Checks under collection	<b>26,397,390</b>	5,224,742
Current accounts	<b>31,545,152</b>	10,405,263
	<b>58,333,386</b>	18,513,062

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS  
For the three-month and six-month periods ended 30 June 2023

**12- PROVISIONS**

	<i>Balance as at 1 January 2023 EGP</i>	<i>Charged during the period EGP</i>	<i>Used during the period EGP</i>	<i>Balance as at 30 June 2023 EGP</i>
Provision for expected claims	5,550,001	-	-	5,550,001
Provision for sales returns*	8,608,104	-	-	8,608,104
	<u>14,158,105</u>	<u>-</u>	<u>-</u>	<u>14,158,105</u>

	<i>Balance as at 1 January 2022 EGP</i>	<i>Charged during the year EGP</i>	<i>Used during the year EGP</i>	<i>Balance as at 31 December 2022 EGP</i>
Provision for expected claims	5,550,001	-	-	5,550,001
Provision for sales returns*	8,711,844	-	(103,740)	8,608,104
	<u>14,261,845</u>	<u>-</u>	<u>(103,740)</u>	<u>14,158,105</u>

\*Provision for sales returns is deducted from sales disclosed in note (19).

**13- TRADE, NOTES AND OTHER PAYABLE**

	<i>30 June 2023 EGP</i>	<i>31 December 2022 EGP</i>
Trade payable	155,750,091	120,246,841
Notes payable	79,708,681	5,423,773
Accrued expenses	44,197,299	50,670,068
Tax authority (other than income tax)	34,187,572	11,782,414
Advances From Customers	11,213,181	10,784,502
Other payables	15,630,417	5,693,153
	<u>340,687,241</u>	<u>204,600,751</u>

Trade payables, accrued expenses and other payables are non-interest bearing.

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### 14- CAPITAL

The Company's authorized capital amounted to EGP 1 billion, whereas the issued and paid up capital amounted to EGP 252,112,680 divided over 1,008,450,720 shares of par value EGP 0.25 each.

Based on the decision of the Extraordinary General Assembly on October 14, 2020, the meeting of the Board of Directors held on January 4, 2023 decided to increase the company's issued and paid-up capital from 250,000,000 Egyptian pounds to 252,112,680 Egyptian pounds, an increase of 2,112,680 Egyptian pounds distributed over 8,450,720 shares, funded by the payments of the beneficiaries of the system provided that the increase is allocated entirely for the benefit of the system of rewarding and motivating the company's employees, so that the company's issued capital after the increase will be 252,112,680 Egyptian pounds paid in full distributed over 1,008,450,720 shares with a nominal value of 0.25 Egyptian pounds. The amount paid under capital increase reach EGP 2,112,680 as of 30 June 2023. According to the bank certificate issued by Arab Bank on January 9, 2023, the company's issued and paid-up capital was increased from 250,000,000 EGP to 252,112,680 EGP, an increase of 2,112,680 EGP distributed over 8,450,720 shares (Note 17).

The following illustrate the structure for shareholders:

	%	<i>No. of shares</i>	<i>Amount EGP</i>
Main Shareholder's Shares	33.13%	334,102,867	83,525,717
Share based payment	2.92%	29,470,000	7,367,500
Other listed Free Shares in Stock Exchange Market	63.95%	644,877,853	161,219,463
	<u>100%</u>	<u>1,008,450,720</u>	<u>252,112,680</u>

The structure for shareholders as at 31 December 2022:

	%	<i>No. of shares</i>	<i>Amount EGP</i>
Main Shareholder's Shares	33.15%	331,574,309	82,893,577
Treasury Shares	2.95%	29,470,000	7,367,500
Other listed Free Shares in Stock Exchange Market	63.90%	638,955,691	159,738,923
	<u>100%</u>	<u>1,000,000,000</u>	<u>250,000,000</u>

#### 15- GENERAL RESERVE

The balance of general reserve - issuance premium is representing the net book value of issuing capital increase shares during 2019 amounted EGP 486,965,000 for issuing 125,000,000 Shares after deducting issuing cost of EGP 64,285,000.

Pursuant to Article (94) of the executive regulations of the Shareholding Companies Law promulgated by Law No. 159 of 1981, an amount of 89,443,610 Egyptian pounds has been transferred to the legal reserve, amounting to 50% of the value of the issued and paid-up capital.

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### 16- TREASURY SHARES

The board members meeting held on February 23, 2022, May 31, 2022 and 4 September 2022 decided to re-purchase treasury shares up to 10% of the total shares of the company's issued capital available in the market.

According to board of director resolutions on 23 February 2022, May 31, 2022 and 4 September 2022, the company purchased 29,470,000 shares from the stock market and held in treasury for a total consideration of EGP 65,926,198. The consideration paid has been accounted for as a reserve in the statement of shareholder's' equity.

During March 2022, the company purchased 20 million shares as treasury shares amounted to 39,694,932 EGP, and according to Article 48 of Law 159 of 1981, the company must dispose its treasury shares to others within a period of not more than one year from obtaining them otherwise it shall reduce its capital by the equivalent of the nominal value of these stocks.

Currently, the company is taking the necessary actions to reduce its capital by the nominal value of the treasury stocks with a total value of 5,000,000 EGP

#### 17- SHARE BASED PAYMENT RESERVE

The company has approved the reward and incentive program for employees, managers and executive board members under the program the company grant the beneficiaries Ordinary share options at the nominal value in accordance with the approval of the Extraordinary General Assembly on October 14, 2020, and this program allows employees, managers and executive board members who benefit from the incentive and reward system to own part of the company's shares in accordance to listing and Trading Rules of Egyptian Stock Exchange under the provisions of Law 159 for year 1981 and its executive regulations and under the provision of law 95 for year 1992 and its executive regulations.

On 30 March 2023 the company activated the reward and incentive program. Giving number of employees, managers and executive board members share options for total of 7,748,502 shares at the nominal value (0.25 EGP per share) on condition of staying in service for the required period till the exercise date on 1 November 2023 an archiving the required performance appraisal. Each employee was granted maximum number of shares according to contracts giving one month period from the exercise date to exercise the purchasing right.

The fair value of the granted shares for numbers of employees were 13,404,908 Egyptian Pound using the price of the share announced in the Egyptian Stock Exchange on the grant date (2.01 EGP for share) before the deduction of the nominal value of shares that would be paid by the beneficiaries in cash.

#### Movement of Equity instruments in the period as follow:

	30 June 2023		31 December 2022	
	Amount EGP	Shares No.	Amount EGP	Shares No.
<b>Balance at 1 January 2023</b>	<b>14,873,267</b>	<b>8,450,720</b>	-	-
Granted during the period / year	<b>5,108,906</b>	<b>7,748,502</b>	14,873,267	8,450,720
Forfeited during the period / year	-	-	-	-
Exercised during the period / year	<b>(14,873,267)</b>	<b>(8,450,720)</b>	-	-
<b>Total shares at the end of period / year</b>	<b>5,108,906</b>	<b>7,748,502</b>	<b>14,873,267</b>	<b>8,450,720</b>

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### 18- CREDIT FACILITIES

The movement of the credit facilities during the period/year is as follows:

	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Opening balance	<b>893,644,592</b>	819,720,928
Used during the period	<b>695,378,434</b>	1,195,291,001
Payment during the period	<b>(533,478,375)</b>	(1,121,367,337)
Ending balance	<b>1,055,544,651</b>	893,644,592
	<i>30 June 2023</i>	<i>31 December 2022</i>
	<i>EGP</i>	<i>EGP</i>
Credit facilities maturing within 12 months	<b>1,055,544,651</b>	893,644,592
Bank credit	<b>8,270,981</b>	11,108,281
	<b>1,063,815,632</b>	904,752,873

The interest rate on the Credit facilities ranges from 8% to 19.25% as of 30 June 2023 (31 December 2022: Range from 8% to 17.75%).

Credit Facilities	Facility amount	<i>30 June 2023</i>	<i>31 December 2022</i>
	EGP	<i>EGP</i>	<i>EGP</i>
CIB	500,000,000	<b>356,950,463</b>	180,248,662
FAB Bank	125,000,000	<b>124,632,425</b>	63,847,436
Arab Bank	88,000,000	<b>71,468,235</b>	73,847,329
ABK Bank	120,000,000	<b>85,719,372</b>	95,136,500
ADIB	150,000,000	<b>149,308,213</b>	131,491,585
Alex Bank	170,000,000	<b>92,259,360</b>	164,828,846
AUB	130,000,000	<b>96,287,826</b>	93,222,510
ENBD	100,000,000	<b>78,918,757</b>	91,021,724
<b>Total Credit Facilities</b>		<b>1,055,544,651</b>	893,644,592

\* The Balance above represents the funds granted for the purchase of raw materials, and packaging in accordance with the initiative of the Central Bank of Egypt to support the industrial sector issued on 12 December 2019 to finance companies with private ownership and small and medium enterprises and support them to reach their investment goals and cover operating expenses.

Some of the above facilities are guaranteed by notes receivables (Note 9).

#### 19- REVENUES

	Six Months ended		Three months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Sale of goods (net)	<b>765,724,416</b>	656,182,470	<b>417,668,977</b>	338,723,116
Toll manufacturing services revenue	<b>73,272,538</b>	51,933,190	<b>31,650,014</b>	26,893,311
	<b>838,996,954</b>	708,115,660	<b>449,318,991</b>	365,616,427

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS For the three-month and six-month periods ended 30 June 2023

#### 20- COST OF REVENUE

	Six Months ended		Three months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Salaries and incentives	62,446,688	48,929,444	32,728,066	24,884,509
Social insurance and other benefit	17,683,751	10,689,087	8,558,793	6,064,557
Raw materials	254,504,668	214,765,188	136,594,799	116,487,479
Spare parts and materials	15,280,124	8,698,132	8,297,656	4,334,600
Government fees and medical stamps	8,037,002	6,660,380	4,302,251	3,730,421
Other operating expenses	32,225,845	20,715,443	15,709,390	9,725,837
Energy expenses	22,141,857	18,777,205	12,904,539	10,670,153
Depreciation and amortization (Note 5,7)	29,527,784	27,305,233	14,853,265	13,928,638
Rent	3,277,489	1,168,559	2,241,269	509,662
Maintenance	14,661,786	8,235,806	8,320,405	4,603,461
	<b>459,786,994</b>	<b>365,944,477</b>	<b>244,510,433</b>	<b>194,939,317</b>

#### 21- SELLING AND MARKETING EXPENSES

	Six Months ended		Three months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Salaries and incentives	63,022,151	58,273,821	33,260,984	29,736,460
Social insurance and other benefit	6,987,461	4,313,392	3,592,007	2,631,978
Depreciation (Note 5&6)	2,503,181	2,326,189	1,262,900	1,183,390
Rent	38,400	25,500	28,800	19,200
Advertising and marketing	82,250,945	70,638,505	48,624,889	38,866,783
	<b>154,802,138</b>	<b>135,577,407</b>	<b>86,769,580</b>	<b>72,437,811</b>

#### 22- GENERAL AND ADMINISTRATIVE EXPENSES

	Six Months ended		Three months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Salaries and incentives	29,181,351	22,564,839	15,510,059	11,519,517
Social insurance and other benefit	1,871,624	1,135,389	947,234	767,489
Professional fees	2,521,078	689,702	1,730,443	468,479
Maintenance	682,860	715,797	385,978	279,404
Depreciation (Note 5)	992,568	990,024	504,088	497,742
Others	5,749,507	4,583,348	3,064,938	2,676,098
	<b>40,998,988</b>	<b>30,679,099</b>	<b>22,142,740</b>	<b>16,208,729</b>

**TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)**

**NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS**

For the three-month and six-month periods ended 30 June 2023

**23- FINANCE INCOME**

	Six Months ended		Three months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Interest from Treasury Bills	30,440,081	27,665,331	14,907,635	13,706,263
Interest from time deposits	331,101	1,634	152,721	15
	<b>30,771,182</b>	<b>27,666,965</b>	<b>15,060,356</b>	<b>13,706,278</b>

**24- FINANCE EXPENSES**

	Six Months ended		Three months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Debit interests	73,881,122	40,842,766	43,863,792	20,073,290
Unwinding interests of lease liabilities	1,067,220	1,041,634	529,201	531,718
Bank Charges	1,185,761	1,786,624	622,984	878,713
	<b>76,134,103</b>	<b>43,671,024</b>	<b>45,015,977</b>	<b>21,483,721</b>

**25- INCOME TAXES**

	Six Months ended		Three months ended	
	30 June 2023	30 June 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Current income tax	(31,462,325)	(32,301,390)	(15,457,867)	(14,335,282)
Deferred income tax	(2,663,908)	(5,343,243)	934,232	(2,329,114)
<b>Income tax expense</b>	<b>(34,126,233)</b>	<b>(37,644,633)</b>	<b>(14,523,635)</b>	<b>(16,664,396)</b>

**DEFERED INCOME TAX**

	<i>Statement of financial position</i>		<i>Statement of profit or loss</i>	
	30 June 2023	31 December 2022	30 June 2023	30 June 2022
	EGP	EGP	EGP	EGP
Depreciation and amortization	(62,945,076)	(58,468,620)	(4,476,456)	(5,558,607)
Provisions	1,936,823	1,936,823	-	(73,705)
Impairment of trade and notes receivables	2,829,565	2,437,135	392,430	(40,439)
Write down of inventory	4,314,030	2,397,681	1,916,349	(89,359)
Share based payment	1,149,504	4,015,782	(2,866,278)	1,470,663
Unrealized foreign exchange differences	(1,504,577)	(3,874,624)	2,370,047	(1,051,796)
<b>Net deferred income taxes</b>	<b>(54,219,731)</b>	<b>(51,555,823)</b>	<b>(2,663,908)</b>	<b>(5,343,243)</b>

## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### RECONCILIATION OF THE EFFECTIVE INCOME TAX RATE

	<i>Tax Rate</i>	<i>30 June 2023</i>	<i>Tax Rate</i>	<i>30 June 2022</i>
		<i>EGP</i>		<i>EGP</i>
Profits before income taxes		<b>147,570,121</b>		162,883,956
Income tax based on tax rate	<b>22.50%</b>	<b>33,203,277</b>	22.50%	36,648,890
Non-deductible expenses		<b>922,956</b>		995,743
Effective Tax Rate	<b>23.13%</b>	<b>34,126,233</b>	23.11%	37,644,633

#### 26- EARNINGS PER SHARE

Basic and diluted earnings per share was calculated by dividing the profits for the period/year available for distribution by the weighted average number of shares outstanding during the period/year as follows:

	<b>Six Months ended</b>		<b>Three months ended</b>	
	<b>30 June 2023</b>	<b>30 June 2022</b>	<b>30 June 2023</b>	<b>30 June 2022</b>
	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>	<b>EGP</b>
Basic and diluted, profit for the period	<b>113,443,888</b>	125,239,323	<b>48,048,175</b>	54,822,961
Weighted average number of shares outstanding after purchase of treasury shares during the period	<b>978,980,720</b>	990,000,000	<b>978,980,720</b>	990,000,000
Share Options for employees and executive board members	<b>6,905,406</b>	7,428,630	<b>6,905,406</b>	7,428,630
Weighted average number of ordinary shares adjusted for the effect of share options of dilution	<b>985,886,126</b>	997,428,630	<b>985,886,126</b>	997,428,630
<b>Earnings per share - Basic</b>	<b>0.1159</b>	0.1265	<b>0.0491</b>	0.0554
<b>Earnings per share - Diluted</b>	<b>0.1151</b>	0.1256	<b>0.0487</b>	0.0550

#### 27- TAX POSITION

##### a) Corporate Tax

- The Company's records were inspected till the year 2013 and the due tax has been paid.
- The years from 2014 to 2017 were inspected as an estimate and were challenged and a decision was issued to re-examine the actual inspection has been done and the dispute is under settlement.
- The years 2018 and 2019 have been inspected and the forms were issued and the dispute are under settlement.

##### b) Salary Tax

- The Company's records were inspected till the period 2015 and the taxes differences were paid and settled.
- Periods from 2016 to 2019 the documents related to the inspection were submitted and the tax due in the settlements was paid.

##### c) Stamp Tax

- The Company's records were inspected till 2013 and the taxes due were paid.
- The years from 2014 to 2020 were inspected and the dispute are under settlement.

##### d) Sales Tax

- The Company's records were inspected till the period 2015 and the due tax has been paid.

##### a) VAT Tax

- The Company's books were examined from 2016 to 2019 and the due tax has been paid.



## TENTH OF RAMADAN FOR PHARMACEUTICAL INDUSTRIES AND DIAGNOSTIC REAGENTS (RAMEDA) (S.A.E)

### NOTES TO THE INTERIM CONDENSED SEPARATE FINANCIAL STATEMENTS

For the three-month and six-month periods ended 30 June 2023

#### 28- RELATED PARTIES

For the purpose of these separate financial statements, parties are considered to be related to the Company, if the Company has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control. Related parties may be individuals or other entities.

##### a) Related party transactions

During the period, the following were the significant related party transactions, which were carried out in the normal course of business on terms agreed between the parties:

Company	Nature of party	Nature of transaction	30 June 2023	30 June 2022
			EGP	EGP
Rameda for Pharmaceuticals trading	Subsidiary	Rent	3,000	3,000
		Purchases	229,443	3,240,550
Ramecare Company	Subsidiary	Rent	3,000	3,000
		Purchases	2,543,375	1,241,820
Ramepharma Company	Subsidiary	Rent	3,000	3,000
		Sales	10,447,711	5,993,223

##### b) Related party balances

Nature of party	30 June 2023		31 December 2022	
	Due from EGP	Due to EGP	Due from EGP	Due to EGP
Rameda for Pharmaceuticals Trading	-	4,921,723	620,366	-
Ramecare Company	-	1,841,792	1,518,083	-
Ramepharma Company	25,046,446	-	22,284,090	-
	<u>25,046,446</u>	<u>6,763,515</u>	<u>24,422,539</u>	<u>-</u>

##### c) Salaries and incentives of key managers

The key manager's compensation during period ended 30 June 2023 and 30 June 2022 is as follow:

	30 June 2023	30 June 2022
	EGP	EGP
Salaries and incentives	23,414,853	16,467,967
Share options for employees, managers, and executive board members	6,536,280	6,536,280
	<u>29,951,133</u>	<u>23,004,247</u>

#### 29- MAJOR EVENTS

On 30 March 2023, the Central Bank of Egypt decided to increase the overnight deposit and lending rates and the price of the main operation of the central bank by 200 basis points, to reach 18.25%, 19.25, and 18.75%, respectively. The credit and discount rates were also raised by 200 basis points, to reach 18.75%.